Jorge Calderón-Parra1,2, Elena Múñez-Rubio1,2, Ana Fernández-Cruz1,2, María Cristina García-Sánchez1, Esther Maderuelo-González1, Marcos López-Dosil3, Marina Calvo-Salvador4, Isolina Baños-Pérez5, Manuel Valle-Falcones6, Antonio Ramos-Martínez1,7. 1. Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 2. Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Majadahonda, Madrid, Spain. 3. Department of Microbiology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 4. Department of Pharmacy, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 5. Department of Internal Medicine, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 6. Department of Neumology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 7. Medicine Department, Universidad Autónoma de Madrid, Madrid, Spain.
Abstract
BACKGROUND: Our objective is to describe the presentation and complications, including relapses, of coronavirus disease 2019 (COVID-19) in patients under anti-CD20 treatments. In addition, to describe viral clearance and determine the safety of reintroducing anti-CD20 treatment. METHODS: Retrospective cohort study of 422 patients under anti-CD20 treatment that was administered from 1 January 2019 to 31 December 2020. RESULTS: Fifty-seven patients were diagnosed with COVID-19 (13.5%). Twenty-five patients (43.9%) required hospital admission. Five patients died (8.8%), and 10 developed severe COVID-19 and acute respiratory distress syndrome. Mortality rate was higher among patients infected during the first 3 months following the last dose of anti-CD20 (14.7% vs 0%, P = .046). The median time of persistence of positive reverse transcription polymerase chain reaction (RT-PCR) was 22 days (IQR 13-40).Nine out of 52 survivors (17.3%) presented relapses. All of them received the last dose of anti-CD20 less than 6 months before the COVID-19 episode. Clinical presentation was fever (n = 8; 88.9%), dyspnea (n = 7; 77.8%), cough (n = 7; 77.8%), worsening of previous infiltrates (n = 5; 55.6%) and new pulmonary infiltrates (n = 8; 88.9%). An increase in lymphocytes with CD4/CD8 ratio inversion was observed in all cases. Among the 25 patients who resumed anti-CD20 drug, 4 (16.0%) presented relapses vs 5/28 among those who did not (17.9%), (P = .857). CONCLUSIONS: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the 6 months after anti-CD20 administration had a worse outcome and a higher mortality rate. The duration of infectivity may be longer. Relapses of COVID-19 occurred in more than 15% and were associated with viral replication. Once the infection is resolved, it is safe to restart treatment with anti-CD20.
BACKGROUND: Our objective is to describe the presentation and complications, including relapses, of coronavirus disease 2019 (COVID-19) in patients under anti-CD20 treatments. In addition, to describe viral clearance and determine the safety of reintroducing anti-CD20 treatment. METHODS: Retrospective cohort study of 422 patients under anti-CD20 treatment that was administered from 1 January 2019 to 31 December 2020. RESULTS: Fifty-seven patients were diagnosed with COVID-19 (13.5%). Twenty-five patients (43.9%) required hospital admission. Five patients died (8.8%), and 10 developed severe COVID-19 and acute respiratory distress syndrome. Mortality rate was higher among patients infected during the first 3 months following the last dose of anti-CD20 (14.7% vs 0%, P = .046). The median time of persistence of positive reverse transcription polymerase chain reaction (RT-PCR) was 22 days (IQR 13-40).Nine out of 52 survivors (17.3%) presented relapses. All of them received the last dose of anti-CD20 less than 6 months before the COVID-19 episode. Clinical presentation was fever (n = 8; 88.9%), dyspnea (n = 7; 77.8%), cough (n = 7; 77.8%), worsening of previous infiltrates (n = 5; 55.6%) and new pulmonary infiltrates (n = 8; 88.9%). An increase in lymphocytes with CD4/CD8 ratio inversion was observed in all cases. Among the 25 patients who resumed anti-CD20 drug, 4 (16.0%) presented relapses vs 5/28 among those who did not (17.9%), (P = .857). CONCLUSIONS: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the 6 months after anti-CD20 administration had a worse outcome and a higher mortality rate. The duration of infectivity may be longer. Relapses of COVID-19 occurred in more than 15% and were associated with viral replication. Once the infection is resolved, it is safe to restart treatment with anti-CD20.
Authors: Vincenzo Scaglione; Salvatore Rotundo; Nadia Marascio; Carmela De Marco; Rosaria Lionello; Claudia Veneziano; Lavinia Berardelli; Angela Quirino; Vincenzo Olivadese; Francesca Serapide; Bruno Tassone; Helen Linda Morrone; Chiara Davoli; Valentina La Gamba; Andrea Bruni; Bruno Mario Cesana; Giovanni Matera; Alessandro Russo; Francesco Saverio Costanzo; Giuseppe Viglietto; Enrico Maria Trecarichi; Carlo Torti Journal: BMC Infect Dis Date: 2022-10-20 Impact factor: 3.667
Authors: Zachary A Yetmar; Ryan B Khodadadi; Maria Teresa Seville; Lisa Brumble; John C O'Horo; Ravindra Ganesh; Raymund R Razonable Journal: Open Forum Infect Dis Date: 2022-04-14 Impact factor: 4.423
Authors: Manfred Nairz; Sabina Sahanic; Alex Pizzini; Anna Böhm; Piotr Tymoszuk; Anna-Maria Mitterstiller; Laura von Raffay; Philipp Grubwieser; Rosa Bellmann-Weiler; Sabine Koppelstätter; Andrea Schroll; David Haschka; Martina Zimmermann; Silvia Blunder; Kristina Trattnig; Helene Naschberger; Werner Klotz; Igor Theurl; Verena Petzer; Clemens Gehrer; John E Mindur; Anna Luger; Christoph Schwabl; Gerlig Widmann; Günter Weiss; Judith Löffler-Ragg; Ivan Tancevski; Thomas Sonnweber Journal: Sci Rep Date: 2022-03-07 Impact factor: 4.379
Authors: Víctor Moreno-Torres; Carmen de Mendoza; Susana Mellor-Pita; María Martínez-Urbistondo; Pedro Durán-Del Campo; Pablo Tutor-Ureta; José-Manuel Vázquez-Comendador; Jorge Calderón-Parra; Elena Múñez-Rubio; Antonio Ramos-Martínez; Ana Fernández-Cruz; Raquel Castejón; Juan-Antonio Vargas-Nuñez Journal: Viruses Date: 2022-07-26 Impact factor: 5.818